Cutoff FFR Values, What to Do in the “Grey Zone”

Original Title: Significance of Intermediate Values of Fractional Flow Reserve in Patients with Coronary Artery Disease. Reference: Julien Adjedj et al. Circulation. 2016 Jan 5. Epub ahead of print.

The fractional flow reserve (FFR) value of 0.75 has been validated against tests for inducible ischemia, whereas the value 0.80 has been widely accepted to guide the clinical practice. All the same, there is a “grey zone” between 0.76 and 0.85 where deciding for one of the two treatment strategies over the other remains arguable.

The study included all patients with single segment disease and an FFR value within the grey area (0.70 – 0.75 and 0.81 – 0.85) between 1997 and 2013. Primary end point was major adverse cardiovascular events (MACE: death, infarction, and any revascularization) within a 5 year follow up.
During this period, 17380 FFR measurements were carried out; 1459 were found in this grey zone and were analyzed. 449 of these were treated with revascularization and 1010 with medical treatment.

In the grey zone, MACE rate was similar between the medical treatment and revascularization groups (13.9% vs. 11.2% respectively; p=0.3). There was a strong trend towards higher death and infarction rates (9.4 vs. 4.8; p=0.06) and higher all cause death rate (7.5 vs. 3.2; p=0.059) in the medical treatment group.

In patients receiving medical treatment, there was a progressive increase in MACE as FFR decreased (de 0.85 a 0.70) especially for proximal lesions; however, patients receiving revascularization did not show this gradient, but a similar MACE rate in all value strata.

Conclusion
FFR in the “grey zone” still has great prognosis value, especially when it comes to proximal lesions. These data confirm the FFR cutoff value ≤ 0.80 is valid to guide our clinical practice.

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...